Immune checkpoint blockade (ICB) therapies, including inhibition of programmed cell death 1 (PD-1) or ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), have been able to induce a lasting response across multiple cancer lineages. The gene discussed is CTLA4; the disease is cancer.